Silver Grove Financial Group’s Denali Therapeutics DNLI Stock Holding History

Silver Grove Financial Group’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26	Buy	+1	New	+$21	﹤0.01%	2429

Other funds holding DNLI

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Silver Grove Financial Group's DNLI Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Denali Therapeutics (DNLI) in Q2 2026: 1 share worth $26. The stake represents ﹤0.01% of the portfolio and ranks #2429 among its holdings.

292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

Silver Grove Financial Group held 1 share of Denali Therapeutics worth $26 as of Q2 2026.
Denali Therapeutics was a new Silver Grove Financial Group position in Q2 2026.
Denali Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2429 holding.
292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.